Research
Dental travel risk — what the peer-reviewed literature actually shows
Honest summary of the published evidence on cross-border dental treatment outcomes. What is well-documented, what is not, and what New Zealand patients should ask before they fly.
The peer-reviewed literature on cross-border dental treatment is sparse, methodologically weak, and dominated by surveys of complications presenting back home rather than outcome studies of source clinics — meaning the published evidence supports neither sweeping endorsement nor sweeping warnings, and decisions should be made at the case-and-clinic level using documented brand, protocol, and warranty terms.
The peer-reviewed literature on cross-border dental treatment is smaller, weaker, and more biased than most patients — or most journalists writing about dental tourism — assume. This page summarises what the published evidence actually supports, what it does not, and what that means for a New Zealand patient making a decision.
We publish this because we think the patient should see the source material rather than rely on either side of a marketing argument.
The shape of the evidence base
Most published research on dental tourism falls into three categories, each with a different limitation:
1. Home-country dentist surveys
Studies that survey dentists in destination countries (the patient’s home country) about complications they have seen from overseas treatment.
Examples: Barrowman RA et al., Australian Dental Journal 2010; Adams K et al., New Zealand Dental Journal 2018; Lunt N et al., NHS evidence review 2014.
The limitation: these surveys capture only the patients who return with complications. They cannot capture the much larger group of patients whose overseas treatment was successful and never required home-country follow-up. The denominator is missing.
This is a classic selection bias. The same survey methodology applied to any sub-specialty of local dentistry would produce a similar profile of “complications seen” without ever telling you the underlying success rate.
2. Health system perspective papers
Policy and health-economic analyses of medical and dental tourism flows.
Examples: Turner L, BMC Health Services Research 2012; Lunt N et al., Health Services and Delivery Research 2014.
The limitation: these are policy papers, not clinical outcome studies. They describe the system-level context (flows, regulation gaps, repatriation costs) but do not produce clinical outcome data.
3. Source-clinic case series
Outcome studies from individual clinics in destination countries.
The limitation: there are very few of these. The clinics most likely to publish their own outcomes are also the clinics most likely to be careful with cases, so even the published series may not represent the broader destination-country market.
What the evidence consistently supports
Despite the weakness of the evidence base, three findings are consistent across the available literature:
- Clinic-level factors dominate country-level factors. Sterilisation discipline, surgical technique, brand documentation, and written records predict outcome more than the country in which treatment was performed. This is consistent with the broader implant survival literature, which shows brand and case factors matter more than location.
- The implant passport (or its absence) is a major predictor of difficult re-treatment. Home-country dentists treating an unknown fixture face a much harder task than dentists treating a documented Nobel Biocare or Straumann fixture. Lack of brand documentation is the single most-cited frustration in the home-country survey literature.
- Communication gaps drive avoidable problems. When the treating clinic does not send records (CBCT, surgical notes, restoration spec, warranty documents) to the home-country dentist, routine follow-up becomes diagnostic puzzle-solving. This is preventable.
What the evidence does not support
The published literature does not support:
- A blanket claim that overseas dental treatment is “unsafe” — the denominator data is missing.
- A blanket claim that overseas dental treatment is “safe” — outcome data from source clinics is sparse.
- Country-level rankings of dental tourism destinations on outcome quality — the evidence base cannot support these.
- Specific complication-rate figures for “dental tourism” as a category — the figures floating in the popular press do not survive scrutiny against the published source material.
What this means in practice
The decision is at the case-and-clinic level, not the country level. A New Zealand patient considering a specific clinic should ask:
| Question | What to ask for |
|---|---|
| Which implant brand will be placed? | Manufacturer warranty document, in writing, before flights are booked |
| What does the written plan say? | Itemised NZD plan with each phase (consultation, surgery, restoration, materials, follow-up) priced separately |
| What is the warranty? | Specific years per material tier; what is covered and what is excluded; whether travel reimbursement applies for re-treatment |
| What records will I receive? | CBCT files; implant passport with lot numbers and batch; written aftercare summary; surgical notes if relevant; copy of all radiographs |
A patient with all four of these can be treated by any competent dentist worldwide if complications arise. A patient with none of these is in a much harder position.
How Picasso aligns with the evidence
Our position on the evidence is straightforward:
- We name every implant brand we use (implant brand transparency) and supply the manufacturer warranty in writing before flights are booked.
- Every patient leaves with an implant passport including lot numbers and batch.
- We supply CBCT files, surgical notes, and written aftercare summary as standard.
- Our warranty terms are published (/warranty/) including travel reimbursement for re-treatment.
- We respond publicly to negative reviews and document corrective action (/reviews/).
- We publish honest contraindication content (/safety/honest-risks/) including who should not travel.
This does not make us immune to the methodological weakness of the published literature — it means we are responding to what the literature consistently shows matters.
What we recommend reading
If you want to read the source material yourself:
- Barrowman RA et al., “Dental implant tourism”, Australian Dental Journal 2010 — first major home-country survey.
- Turner L, “Cross-border dental care: dental tourism and patient mobility”, BMC Health Services Research 2012 — policy and ethics overview.
- Lunt N et al., “Implications for the NHS of inward and outward medical tourism”, Health Services and Delivery Research 2014 — UK NHS perspective with detailed methodology critique.
- Adams K et al., “Dental tourism: a survey of New Zealand dentists”, New Zealand Dental Journal 2018 — NZ-specific home-country survey, with the same selection-bias limitation as the others.
Read these critically. Ask of every “complication rate” figure: what was the denominator?
See also
- Is it safe? — the umbrella safety answer for New Zealand patients.
- Honest risks — the trade-offs and risks we will not minimise.
- Implant brand transparency — which fixtures we use and the warranty per system.
- What if something goes wrong? — warranty and dispute pathway.
- Implant survival — 10-year data — our case archive data with peer-reviewed comparison.
About this page
Medically reviewed by
Dr. Emily Nguyen
Founding Clinical Director, Picasso Dental Clinic
DDS · Founder and Clinical Director, Picasso Dental Clinic group
Clinical focus: Cosmetic dentistry · Veneers · Smile design
Dr. Emily Nguyen founded Picasso Dental Clinic in 2013 (originally Serenity International Dental Clinic) and led its 2023 rebrand. She sets clinical standards across the group's six branches in Hanoi, Da Nang, Ho Chi Minh City, and Da Lat, and personally reviews cosmetic protocols including the Portrait Sitting workflow for veneers and smile makeovers.
Frequently asked questions
Does the peer-reviewed literature say dental travel is unsafe?
No. The peer-reviewed literature does not support a sweeping safety claim in either direction. The published evidence is dominated by surveys of complications presenting to home-country dentists — those surveys have selection bias because they capture only failures, not the much larger number of successful outcomes that never present back home.
What does the literature actually show?
Three consistent findings: (1) complication rates correlate strongly with clinic-level factors (brand documentation, sterilisation, surgical technique) rather than country of treatment; (2) lack of an implant passport or written record is the single biggest predictor of difficult re-treatment back home; (3) communication gaps between treating clinic and home-country dentist drive the most common preventable problems.
Where is the literature weakest?
Outcome data from source clinics is almost entirely missing from the published literature. Most studies survey home-country complications without any link to the original treating clinic's outcome data. This is the biggest evidence gap and makes country-vs-country comparisons unreliable.
What should a New Zealand patient ask the clinic before flying?
Four questions: (1) which implant brand, with the manufacturer warranty document; (2) the written treatment plan with each step priced in NZD; (3) the warranty terms including re-treatment cover; (4) whether the clinic will supply records (CBCT, implant passport, written aftercare summary) to your New Zealand dentist. Picasso supplies all four by default.